{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:11:25Z","timestamp":1790071885199,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06775-6","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:48:32Z","timestamp":1790070512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oral solifenacin suspension in the management valve bladder: a pilot study"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4831-5795","authenticated-orcid":false,"given":"Ramesh","family":"Babu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharanendran","family":"Heera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathyamurthy","family":"Arunaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"6775_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11934-002-0021-8","volume":"3","author":"E Jaureguizar","year":"2002","unstructured":"1.Jaureguizar E, L\u00f3pez-Pereira P, Martinez-Urrutia MJ (2002) The valve bladder: Etiology and outcome. Curr Urol Rep 3:115\u2013120. https:\/\/doi.org\/10.1007\/s11934-002-0021-8","journal-title":"Curr Urol Rep"},{"key":"6775_CR2","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.jpurol.2013.06.007","volume":"9","author":"P Lopez Pereira","year":"2013","unstructured":"2.Lopez Pereira P, Martinez Urrutia MJ, Espinosa L, Jaureguizar E (2013) Long-term consequences of posterior urethral valves. J Pediatr Urol 9:590\u2013596. https:\/\/doi.org\/10.1016\/j.jpurol.2013.06.007","journal-title":"J Pediatr Urol"},{"key":"6775_CR3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0022-5347(05)65453-5","volume":"167","author":"SA Koff","year":"2002","unstructured":"3.Koff SA, Mutabagani KH, Jayanthi VR (2002) The valve bladder syndrome: pathophysiology and treatment with nocturnal bladder emptying. J Urol 167:291\u2013297. https:\/\/doi.org\/10.1016\/S0022-5347(05)65453-5","journal-title":"J Urol"},{"key":"6775_CR4","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/S0022-5347(05)65796-5","volume":"166","author":"KI Glassberg","year":"2001","unstructured":"4.Glassberg KI (2001) The valve bladder syndrome: 20 years later. J Urol 166:1406\u20131414","journal-title":"J Urol"},{"key":"6775_CR5","first-page":"980","volume":"43","author":"R Babu","year":"2006","unstructured":"5.Babu R (2006) Effectiveness of tolterodine in non-neurogenic voiding dysfunction. Indian Pediatr 43:980","journal-title":"Indian Pediatr"},{"key":"6775_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00383-021-05040-8","volume":"38","author":"R Babu","year":"2022","unstructured":"6.Babu R, Chittibabu T, Chadha S (2022) Safety and short-term efficacy of mirabegron in children with valve bladder: a pilot study. Pediatr Surg Int 38:493\u2013498. https:\/\/doi.org\/10.1007\/s00383-021-05040-8","journal-title":"Pediatr Surg Int"},{"key":"6775_CR7","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.juro.2012.03.068","volume":"188","author":"JT Casey","year":"2012","unstructured":"7.Casey JT, Hagerty JA, Maizels M, Chaviano AH, Yerkes E, Lindgren BW et al (2012) Early administration of oxybutynin improves bladder function and clinical outcomes in newborns with posterior urethral valves. J Urol 188:1516\u20131520. https:\/\/doi.org\/10.1016\/j.juro.2012.03.068","journal-title":"J Urol"},{"key":"6775_CR8","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.eururo.2004.11.004","volume":"47","author":"F Haab","year":"2005","unstructured":"8.Haab F, Cardozo L, Chapple C, Ridder AM (2005) Long-Term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 47:376\u2013384. https:\/\/doi.org\/10.1016\/j.eururo.2004.11.004","journal-title":"Eur Urol"},{"key":"6775_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1586\/ecp.09.3","volume":"2","author":"D Robinson","year":"2009","unstructured":"9.Robinson D, Cardozo L (2009) Solifenacin: pharmacology and clinical efficacy. Expert Rev Clin Pharmacol 2:239\u2013253. https:\/\/doi.org\/10.1586\/ecp.09.3","journal-title":"Expert Rev Clin Pharmacol"},{"key":"6775_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.eururo.2016.02.007","volume":"70","author":"A-S Blais","year":"2016","unstructured":"10.Blais A-S, Nadeau G, Moore K, Genois L, Bolduc S (2016) Prospective pilot study of mirabegron in pediatric patients with overactive bladder. Eur Urol 70:9\u201313. https:\/\/doi.org\/10.1016\/j.eururo.2016.02.007","journal-title":"Eur Urol"},{"key":"6775_CR11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0022-5347(17)56985-2","volume":"121","author":"SB Bauer","year":"1979","unstructured":"11.Bauer SB, Dieppa RA, Labib KK, Retik AB (1979) The bladder in boys with posterior urethral valves: a urodynamic assessment. J Urol 121:769\u2013773. https:\/\/doi.org\/10.1016\/S0022-5347(17)56985-2","journal-title":"J Urol"},{"key":"6775_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1046\/j.1464-410X.1997.26922.x","volume":"79","author":"JW Duckett","year":"1997","unstructured":"12.Duckett JW (1997) Are \u2018valve bladders\u2019 congenital or iatrogenic? Br J Urol 79:271\u2013275. https:\/\/doi.org\/10.1046\/j.1464-410X.1997.26922.x","journal-title":"Br J Urol"},{"key":"6775_CR13","first-page":"66","volume":"5","author":"ME Mitchell","year":"1996","unstructured":"13.Mitchell ME, Close CE (1996) Early primary valve ablation for posterior urethral valves. Semin Pediatr Surg 5:66\u201371","journal-title":"Semin Pediatr Surg"},{"key":"6775_CR14","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.juro.2010.03.124","volume":"184","author":"S Bolduc","year":"2010","unstructured":"14.Bolduc S, Moore K, Nadeau G, Lebel S, Lamontagne P, Hamel M (2010) Prospective open label study of solifenacin for overactive bladder in children. J Urol 184:1668\u20131673. https:\/\/doi.org\/10.1016\/j.juro.2010.03.124","journal-title":"J Urol"},{"key":"6775_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.5489\/cuaj.1356","volume":"8","author":"G Nadeau","year":"2014","unstructured":"15.Nadeau G, Schr\u00f6der A, Moore K, Genois L, Lamontagne P, Hamel M et al (2014) Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study. Can Urol Assoc J 8:118\u2013123. https:\/\/doi.org\/10.5489\/cuaj.1356","journal-title":"Can Urol Assoc J"},{"key":"6775_CR16","doi-asserted-by":"publisher","first-page":"180e1","DOI":"10.1016\/j.jpurol.2019.12.012","volume":"16","author":"I Franco","year":"2020","unstructured":"16.Franco I, Hoebeke P, Baka-Ostrowska M, Bolong D, Davies LN, Dahler E et al (2020) Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies. J Pediatr Urol 16:180e1. https:\/\/doi.org\/10.1016\/j.jpurol.2019.12.012","journal-title":"J Pediatr Urol"},{"key":"6775_CR17","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.juro.2017.05.038","volume":"198","author":"D Newgreen","year":"2017","unstructured":"17.Newgreen D, Bosman B, Hollestein-Havelaar A, Dahler E, Besuyen R, Snijder R et al (2017) Long-term safety and efficacy of solifenacin in children and adolescents with overactive bladder. J Urol 198:928\u2013936. https:\/\/doi.org\/10.1016\/j.juro.2017.05.038","journal-title":"J Urol"},{"key":"6775_CR18","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/nau.22945","volume":"36","author":"G Del Amarenco","year":"2017","unstructured":"18.Amarenco G, Sutory M, Zachoval R, Agarwal M, Del Popolo G, Tretter R et al (2017) Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: results from the double-blind, randomized, active\u2010 and placebo\u2010controlled SONIC urodynamic study. Neurourol Urodyn 36:414\u2013421. https:\/\/doi.org\/10.1002\/nau.22945","journal-title":"Neurourol Urodyn"},{"key":"6775_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.eururo.2016.08.061","volume":"71","author":"D Newgreen","year":"2017","unstructured":"19.Newgreen D, Bosman B, Hollestein-Havelaar A, Dahler E, Besuyen R, Sawyer W et al (2017) Solifenacin in children and adolescents with overactive bladder: results of a phase 3 randomised clinical trial. Eur Urol 71:483\u2013490. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.061","journal-title":"Eur Urol"},{"key":"6775_CR20","doi-asserted-by":"publisher","first-page":"e00684","DOI":"10.1002\/prp2.684","volume":"8","author":"S den Tannenbaum","year":"2020","unstructured":"20.Tannenbaum S, den Adel M, Krauwinkel W, Meijer J, Hollestein-Havelaar A, Verheggen F et al (2020) Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity. Pharmacol Res Perspect 8:e00684. https:\/\/doi.org\/10.1002\/prp2.684","journal-title":"Pharmacol Res Perspect"},{"key":"6775_CR21","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.juro.2009.05.100","volume":"182","author":"P De Hoebeke","year":"2009","unstructured":"21.Hoebeke P, De Pooter J, De Caestecker K, Raes A, Dehoorne J, Van Laecke E et al (2009) Solifenacin for therapy resistant overactive bladder. J Urol 182:2040\u20132044. https:\/\/doi.org\/10.1016\/j.juro.2009.05.100","journal-title":"J Urol"},{"key":"6775_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3346\/jkms.2017.32.2.329","volume":"32","author":"SD Lee","year":"2017","unstructured":"22.Lee SD, Chung JM, Kang D, Ryu DS, Cho WY, Park S (2017) Efficacy and Tolerability of Solifenacin 5 mg Fixed Dose in Korean Children with Newly Diagnosed Idiopathic Overactive Bladder: a Multicenter Prospective Study. J Korean Med Sci 32:329. https:\/\/doi.org\/10.3346\/jkms.2017.32.2.329","journal-title":"J Korean Med Sci"},{"key":"6775_CR23","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1159\/000515992","volume":"105","author":"MG Soliman","year":"2021","unstructured":"23.Soliman MG, El-Abd S, El-Gamal OM, Raheem AA, Abou-Ramadan AR, El-Abd AS (2021) Mirabegron versus solifenacin in children with overactive bladder: prospective randomized single-blind controlled trial. Urol Int 105:1011\u20131017. https:\/\/doi.org\/10.1159\/000515992","journal-title":"Urol Int"},{"key":"6775_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12894-024-01486-9","volume":"24","author":"Y Hu","year":"2024","unstructured":"24.Hu Y, Zhang H (2024) Efficacy and safety of solifenacin combined with biofeedback in children with overactive bladder. BMC Urol 24:97.","journal-title":"BMC Urol"},{"key":"6775_CR25","doi-asserted-by":"publisher","first-page":"19e1","DOI":"10.1016\/j.jpurol.2022.09.014","volume":"19","author":"G Raman","year":"2023","unstructured":"25.Raman G, Tunnicliffe D, Lai E, Bennett T, Caldwell P (2023) Safety and tolerability of solifenacin in children and adolescents with overactive bladder- a systematic review. J Pediatr Urol 19:19e1. https:\/\/doi.org\/10.1016\/j.jpurol.2022.09.014","journal-title":"J Pediatr Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06775-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06775-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06775-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:48:33Z","timestamp":1790070513000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06775-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6775"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06775-6","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CSD-MED\/25\/MAR\/114\/54.","order":2,"name":"Ethics","label":"IRB approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"686"}}